Form 3 - Initial statement of beneficial ownership of securities
01 Novembre 2024 - 9:30PM
Edgar (US Regulatory)
Exhibit 24.1
LIMITED POWER OF ATTORNEY
FOR SECTION 16 REPORTING OBLIGATIONS
Know all by these presents, that the undersigned
hereby makes, constitutes and appoints each of Steven Kelly, Richard Morris and Eric Siegel, signing singly and each acting individually,
as the undersigned’s true and lawful attorney-in-fact with full power and authority as hereinafter described to:
(1) execute
for and on behalf of the undersigned, in the undersigned’s capacity as an officer or director of Carisma Therapeutics Inc. (the
“Company”), Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities
Exchange Act of 1934 and the rules thereunder (the “Exchange Act”);
(2) do
and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute
any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form
with the United States Securities and Exchange Commission (the “SEC”) and any stock exchange or similar authority, including
without limitation the filing of a Form ID, Update Passphrase, or any other application materials to enable the undersigned to gain or
maintain access to the Electronic Data Gathering, Analysis and Retrieval system of the SEC;
(3) seek
or obtain, as the undersigned’s representative and on the undersigned’s behalf, information regarding transactions in the
Company’s securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned
hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such
release of information; and
(4) take
any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be
of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such
attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such
terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.
The undersigned hereby grants to each such attorney-in-fact
full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise
of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally
present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney
and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such
capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned’s
responsibilities to comply with Section 16 of the Exchange Act. The undersigned acknowledges that neither the Company nor the foregoing
attorneys-in-fact assume (i) any liability for the undersigned’s responsibility to comply with the requirement of the Exchange
Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the
undersigned for profit disgorgement under Section 16(b) of the Exchange Act.
This Power of Attorney shall remain in full force
and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings
of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused
this Power of Attorney to be executed as of October 25, 2024.
|
/s/ Sohanya Cheng |
|
Sohanya Cheng |
Grafico Azioni Carisma Therapeutics (NASDAQ:CARM)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Carisma Therapeutics (NASDAQ:CARM)
Storico
Da Dic 2023 a Dic 2024